Plaque Psoriasis
Oral IL-23 inhibitor icotrokinra shows efficacy for plaque psoriasis
New, positive topline data found icotrokinra to be effective for the treatment of moderate to severe plaque psoriasis in patients aged 12 years and older, Protagonist Therapeutics and Johnson & Johnson announced.
FDA expands approval of Stelara biosimilar Selarsdi to include UC, Crohn’s disease
The FDA approved the Stelara biosimilar, Selarsdi, as a 130 mg/26 mL single-dose IV infusion for adult patients with Crohn’s disease and ulcerative colitis, Alvotech and Teva Pharmaceuticals announced in a press release.
FDA approves higher-dose Bimzelx prefilled syringes, autoinjectors
The FDA has approved 320 mg pre-filled syringes and autoinjectors of Bimzelx for the treatment of active psoriatic arthritis with coexisting moderate-to-severe plaque psoriasis, according to a press release from UCB.
Novel TYK2 inhibitor ICP-488 shows efficacy, safety in plaque psoriasis
ICP-488 demonstrated “excellent” efficacy and safety for the treatment of moderate to severe plaque psoriasis in adults, InnoCare Pharma announced in a press release.
TYK-2 inhibitor effective over 7 months for treatment of plaque psoriasis
ESK-001 demonstrates continued efficacy for the treatment of moderate to severe plaque psoriasis over the span of 7 months, according to a late-breaker presentation at the European Academy of Dermatology and Venereology Congress.
FDA accepts supplemental application for Zoryve foam for scalp, body psoriasis
The FDA has accepted Arcutis Biotherapeutics’ supplemental new drug application for Zoryve foam 0.3% for the treatment of scalp and body psoriasis in adults and adolescents aged 12 years and older, the company announced in a press release.
Otezla available in US for treatment of plaque psoriasis in children, adolescents
Otezla is now available in the U.S. for the treatment of moderate to severe plaque psoriasis in children and adolescents aged 6 years and older, Amgen announced in a press release.
Artax completes patient enrollment in phase 2a trial of AX-158 for psoriasis
Artax Biopharma has recruited all 30 patients to a phase 2a clinical trial of AX-158, its investigative Nck modulator for autoimmune diseases, the company announced in a press release.
Q&A: Expert discusses causes of vitiligo as Kim Kardashian opens up about son’s diagnosis
With Kim Kardashian speaking out about her son’s experience with vitiligo, Healio Dermatology sat with an expert to discuss the condition in the adult and pediatric populations.
EU approves 320 mg Bimzelx, 2 mL devices for multiple inflammatory diseases
The European Commission has granted marketing authorization for two devices that administer Bimzelx for the treatment of multiple inflammatory diseases, UCB announced in a press release.